Camilo Quevedo
MSc, PhD
Business Manager (LICR & CIO)
I am a business manager at the University of Oxford, supporting the Ludwig Institute for Cancer Research and The Centre for Immuno-Oncology. As a business manager, I provide operational, financial and strategic support to ensure our high standards and values are mantained, while we continue our cutting edge research in cancer across both institutions. During my career in administration, I have also provided management support to other NDM units such as The Centre for Human Genetics and The Jenner Institute.
Recent publications
-
Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds.
Journal article
Cruz-Migoni A. et al, (2019), Proceedings of the National Academy of Sciences of the United States of America, 116, 2545 - 2550
-
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
Journal article
Quevedo CE. et al, (2018), Nature Communications, 9
-
Correction: BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions
Journal article
Bery N. et al, (2018), eLife, 7
-
BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions
Journal article
Bery N. et al, (2018), eLife, 7
-
Abstract
Journal article
(2018)